CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein

The adaptive immune response to severe acute respiratory coronavirus 2 (SARS-CoV-2) is important for vaccine development and in the recovery from disease 2019 (COVID-19). Men cancer patients have been reported be at higher risks of contracting virus developing more forms COVID-19. Prostate (PCa) may associated with both these risks. We show that CD4 + T cells SARS-CoV-2-unexposed hormone-refractory (HR) metastatic PCa had decreased cell responses antigens SARS-CoV-2 spike glycoprotein but not spiked ‘common cold’-associated human 229E (HCoV-229E) as compared healthy male volunteers who responded comparably HCoV-229E- SARS-CoV-2-derived antigens. Moreover, HCoV-229E antigen-elicited cross-reacted impaired vaccination, cross-reactivity can mediate antibody-dependent enhancement (ADE) These findings highlight potential increased vulnerability